Arrowhead plummets on FDA partial hold
This article was originally published in Scrip
Shares of biotech Arrowhead Research plunged 28% on 12 January after the company disclosed the FDA had imposed a partial clinical hold on a trial of the firm's chronic hepatitis B infection drug ARC-520.
You may also be interested in...
Shares in US biotech Arrowhead Pharmaceuticals took a tumble after the FDA put a clinical hold on one of its small interfering RNAs (siRNAs) Phase II programs in hepatitis B because of concerns over a delivery vehicle that is also used in two of its other Phase II candidates.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.